Infection control in the multidrug-resistant era: Tending the human microbiome

Clinical Infectious Diseases

Volumn 54, Issue 5, 2012, Pages 707-713

  Tosh, Pritish K ^a,b   McDonald, L Clifford ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BISMUTH; CEFOPERAZONE; CIPROFLOXACIN; METRONIDAZOLE; PNEUMOCOCCUS VACCINE; PROBIOTIC AGENT; VANCOMYCIN;

ANTIMICROBIAL THERAPY; ARTICLE; COMMENSAL; CONTROL STRATEGY; HOST; HUMAN; INFECTION CONTROL; MICROBIAL COLONIZATION; MICROBIOME; MICROFLORA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOSIS; DRUG RESISTANCE, MULTIPLE; HUMANS; INFECTION CONTROL; METAGENOME; PUBLIC HEALTH; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84856935253     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir899     Document Type: Article

References (47)

1. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007; 128:1037-50.
2. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenemresistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39:55-60.
3. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
4. Peterson J, Garges S, Giovanni M, et al. The NIH human microbiome project. Genome Res 2009; 19:2317-23.
5. Licht TR, Christensen BB, Krogfelt KA, Molin S. Plasmid transfer in the animal intestine and other dynamic bacterial populations: the role of community structure and environment. Microbiology 1999; 145: 2615-22.
6. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycinresistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51:231-8.
7. Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis 2010; 14(Suppl 4):S3-5.
8. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011; 364:1407-18.
9. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011; 364:1419-30.
10. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52:848-55.
11. Sohn AH, Ostrowsky BE, Sinkowitz-Cochran RL, Quirk SB, Jarvis WR. Evaluation of a successful vancomycin-resistant Enterococcus prevention intervention in a community of health care facilities. Am J Infect Control 2001; 29:53-7.
12. Cusini A, Rampini SK, Bansal V, et al. Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. PLoS One 2010; 5:e14011.
13. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163:972-8.
14. Charani E, Cooke J, Holmes A. Antibiotic stewardship programmes-what's missing? J Antimicrob Chemother 2010; 65:2275-7.
15. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008; 24:4-10.
16. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473:174-80.
17. Shreiner A, Huffnagle GB, Noverr MC. The "microflora hypothesis" of allergic disease. Adv Exp Med Biol 2008; 635:113-34.
18. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107:14691-6.
19. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:e280.
20. Dethlefsen L, Relman DA. Microbes and Health Sackler Colloquium: incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108(Suppl 1):4554-61.
21. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009; 77: 2367-75.
22. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; (108(Suppl 1):4554-61.
23. Robinson CJ, Bohannan BJ, Young VB. From structure to function: the ecology of host-associated microbial communities. Microbiol Mol Biol Rev 2010; 74:453-76.
24. Adams DA, RiggsMM, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007; 51:2674-8.
25. Hoyen CK, Pultz NJ, Paterson DL, Aron DC, Donskey CJ. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2003; 47:3610-12.
26. Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG. Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J Infect Dis 2010; 201:534-43.
27. Paschke AA, Zaoutis T, Conway PH, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics 2010; 125:664-72.
28. Rice LB. Antibiotics and gastrointestinal colonization by vancomycinresistant enterococci. Eur J Clin Microbiol Infect Dis 2005; 24:804-14.
29. Schjorring S, Struve C, Krogfelt KA. Transfer of antimicrobial resistance plasmids from Klebsiella pneumoniae to Escherichia coli in the mouse intestine. J Antimicrob Chemother 2008; 62:1086-93.
30. Tsai HT, Wang JT, Chen CJ, Chang SC. Association between antibiotic usage and subsequent colonization or infection of extensive drugresistant Acinetobacter baumannii: a matched case-control study in intensive care units. Diagn Microbiol Infect Dis 2008; 62:298-305.
31. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 2011; 9: 356-68.
32. Brandl K, Plitas G, Mihu CN, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008; 455: 804-7.
33. Pitout JD. IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs 2009; 10:838-44.
34. Khoder M, Tsapis N, Domergue-Dupont V, Gueutin C, Fattal E. Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. Eur J Pharm Sci 2010; 41:281-8.
35. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15:285-9.
36. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1:1156-60.
37. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44:551-61.
38. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44:354-60.
39. US Food and Drug Administration (FDA). Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/UCM229312.pd. Accessed 31 October 2011.
40. Mohamadzadeh M, Pfeiler EA, Brown JB, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA 2011; 108(Suppl 1):4623-30.
41. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189:1565-73.
42. Coronado F, Nicholas JA, Wallace BJ, et al. Community-associated methicillin-resistant Staphylococcus aureus skin infections in a religious community. Epidemiol Infect 2007; 135:492-501.
43. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:752-60.
44. van Gils EJ, Hak E, Veenhoven RH, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 2011; 6:e20229.
45. Lee GM, Huang SS, Rifas-Shiman SL, et al. Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis 2009; 9:110.
46. Ruimy R, Angebault C, Djossou F, et al. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans? J Infect Dis 2010; 202:924-34.
47. Donlan RM. Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clinical Infect Dis 2011; 52:1038-45.